12月10日晚，海正药业（600267）（600267.SH）公告披露，广州医药股份有限公司（下称"广州医 药"）将斥资5亿元，收购上市公司全资子公司浙江省医药工业有限公司（下称"浙江医药 （600216）"），这是几天内第二起大型医药流通企业的跨省并购。 目前，在国内药品批发行业，国药集团、上海医药（601607）、华润医药、九州通（600998），以及重 庆医药—中国医药（600056）联合体2024年主营收入分列前5位，且年收入规模全部超过1000亿元，这 对于规模相对较小、且业务主要集中在各省区域的医药流通企业形成较大的竞争压力。在此背景下，通 过跨省并购提升规模，拓展业务范围和领域，成为一些医药流通企业的应对之策。 值得注意的是，广州医药东进收购浙江医药前，已将并购之手"伸"到了江苏。今年9月底，广药旗下的 广州医药二期产业基金，斥资7.49亿元买下南京医药（600713）11.04%的股份，成了这家江苏老牌医药 流通企业的第二大股东。 11月18日，2025年广药集团、广药白云山战略合作研讨会在南京举办。广药集团党委书记、董事长李小 军在会上表示，面对医药健康行业新变化，广药集团正向着"再造一个新 ...

截至12月8日收盘，青蒿素概念下跌0.51%，位居概念板块跌幅榜前列，板块内，德龙汇能、百花医 药、新和成等跌幅居前。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 共封装光学(CPO) | 4.72 | 天津自贸区 | -0.99 | | F5G概念 | 4.30 | 草甘膦 | -0.86 | | 光纤概念 | 3.67 | 青蒿素 | -0.51 | | 铜缆高速连接 | 3.57 | 煤炭概念 | -0.51 | | 福建自贸区 | 3.44 | 高股息精选 | -0.38 | | PET铜箔 | 3.02 | 超级品牌 | -0.34 | | 海南自贸区 | 3.00 | 金属锌 | -0.32 | | WiFi 6 | 3.00 | 大豆 | -0.31 | | 光刻机 | 3.00 | 啤酒概念 | -0.31 | | 海峡两岸 | 2.98 | 共享单车 | -0.29 | 资金面上看，今日青蒿素概念板块获主力资金净流出0.62亿元，其中，5股获主力资金净流出，净流出 资金居首的是德龙汇能， ...

浙江医药（600216.SH）12月5日在投资者互动平台表示，公司控股子公司新码生物至香港联交所上市 一事目前正在筹备中，仍有相当的不确定性。不论新码生物是否完成在香港联交所上市，公司目前并无 放弃新码生物控制权的计划，新码生物的财务报表将持续作为公司合并财务报表的一部分，新码生物也 将持续作为公司A股上市实体的组成部分。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司发布信息称"拟将抗癌药领域分拆为新码生物在联 交所上市"。公司拓宽融资渠道作为中小投资者本应该感到高兴，但上海主板市场股价长期低迷。投资 者希望抗癌药上市能够得到价值投资回报，但公司的做法让投资者丧失信心。 ...

每经AI快讯，有投资者在投资者互动平台提问：公司有无流感相关药物或者原料药产品？有无这方面 研发的布局？ 浙江医药（600216.SH）12月5日在投资者互动平台表示，公司部分抗生素产品在部分呼吸道疾病的临 床治疗中有所应用，公司目前处于临床阶段的在研项目并无在流感方面的布局。 （文章来源：每日经济新闻） ...

人民财讯12月5日电，浙江医药(600216)12月5日在互动平台表示，公司对钠创新能源的投资属于财务投 资，该投资目前对公司合并财务报表的影响并不重大，公司并不参与钠创新能源的经营管理，也无相关 信息可供披露。 转自：证券时报 ...

内容概要：医药级鱼油因富含高纯度EPA和DHA，在心血管疾病预防、脑部健康维护等医疗领域应用价 值突出。尤其是高纯度鱼油处方药在降血脂、抗血栓等方面的临床价值日益凸显，是鱼油行业中高附加 值的核心增长方向。近年来，随着消费者健康意识的提高，人口老龄化加速，慢性病发病率的上升，全 球医药级鱼油需求增长。2024年全球医药级鱼油销量3.14万吨，较2023年增加0.59万吨；预计2025年全 球医药级鱼油销量约3.16万吨。医药产业作为我国战略性新兴产业，受到国家重点支持，药用级鱼油行 业迎来发展机遇。随着"健康中国"战略的指引和赋能，医药级鱼油行业实现跨越式发展。2024年中国医 药级鱼油销量0.55万吨，较2023年增加0.11万吨；预计2025年中国球医药级鱼油销量约0.6万吨。 一、医药级鱼油行业定义及特点 鱼油（FishOil）是一种从多脂鱼类中提取的油脂，富含二十碳五烯酸（EPA）和二十二碳六烯酸 （DHA，俗称脑黄金）等多种n-3系多不饱和脂肪酸。鱼油分为粗鱼油和精制鱼油，精制鱼油按目标消 费群体以可以分为饲料级鱼油、医药级鱼油、食品级鱼油。其中，医药级鱼油是一种经过科学验证、用 于特定医疗目的的处 ...

青蒿素概念资金流入榜 | 代码 | 简称 | 今日涨跌幅 | 今日换手率 | 主力资金流量（万 | 主力资金净流入比率 | | --- | --- | --- | --- | --- | --- | | | | （%） | （%） | 元） | （%） | | 600267 | 海正药 业 | 2.49 | 1.25 | 299.33 | 1.88 | | 600196 | 复星医 药 | -0.15 | 0.38 | 177.88 | 0.82 | | 600422 | 昆药集 团 | 0.30 | 0.39 | 140.40 | 3.59 | | 002923 | 润都股 份 | -0.50 | 1.47 | -235.00 | -4.49 | | 600216 | 浙江医 药 | -0.07 | 0.49 | -350.82 | -5.28 | | 600062 | 华润双 鹤 | 0.75 | 0.51 | -801.15 | -8.02 | | 002001 | 新和成 | 0.21 | 0.58 | -817.72 | -1.88 | | 600721 | 百花医 药 | -2.20 | 4.59 ...

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [2] Core Views - The pharmaceutical and biotechnology industry index experienced a decline of 4.40%, ranking 23rd among 31 primary industries, underperforming the CSI 300 index which fell by 2.19% [6][18] - The valuation of the pharmaceutical and biotechnology industry as of November 28, 2025, is a PE (TTM overall method, excluding negative values) of 29.46x, down from 30.89x in the previous period, indicating a downward trend and below the average [22] - The report highlights potential beneficiaries from the upcoming ASH data, particularly in blood diseases and companies with solid grassroots channels, as well as those with differentiated advantages in oncology, autoimmune, and rare disease products [10] Summary by Sections Industry Review - The pharmaceutical and biotechnology industry index fell by 4.40%, with chemical preparations and medical devices showing declines of 2.86% and 2.95% respectively, while offline pharmacies and vaccines saw larger declines of 8.22% and 6.42% [6][18] - The PE ratio for the pharmaceutical and biotechnology industry is 29.46x, with the highest valuations in the vaccine (47.56x), hospital (41.17x), and medical device (36.77x) sectors, while pharmaceutical circulation has the lowest at 14.58x [22] Important Industry News - The National Administration of Traditional Chinese Medicine and the National Healthcare Security Administration released a directory for traditional Chinese medicine diseases suitable for disease-based payment [26][27] - AstraZeneca's drug "Durvalumab" received FDA approval for a new indication in perioperative treatment of gastric cancer [32] - Otsuka Pharmaceutical's new drug for IgA nephropathy, "Sibeprenlimab," has been approved by the FDA [38] - Bayer's first-in-class lung cancer drug "Sevabertinib" has been approved by the FDA for specific patient populations [40] Investment Recommendations - Focus on innovative pharmaceutical companies that may benefit from the medical insurance or commercial insurance directories, blood cancer targets with imminent ASH data releases, and biotech and CXO leaders with solid technology platforms and international collaboration expectations [10]

Core Viewpoint - Zhejiang Medicine is actively expanding its financing channels and improving its industrial chain layout through the planned spin-off of its subsidiary, New Code Biology, for a listing in Hong Kong, alongside significant investments in its main business [1][2]. Group 1: Spin-off and Investment Plans - Zhejiang Medicine announced plans to spin off its subsidiary, New Code Biology, for a Hong Kong listing to optimize resource allocation and broaden financing channels, aiming to enhance its biopharmaceutical business and overall profitability [2][3]. - New Code Biology, a leader in the vitamin sector, focuses on the research and production of biopharmaceuticals and has recently acquired strategic assets to strengthen its R&D pipeline [2]. - The spin-off will not affect Zhejiang Medicine's control over New Code Biology or its other business segments, maintaining operational stability [2][3]. Group 2: Financial Performance - For the first three quarters of 2025, Zhejiang Medicine reported a revenue decline of 5.87% to 66.95 billion, but achieved a net profit of 9.33 billion, reflecting a year-on-year growth of 9.83% [4][5]. - The company’s operating cash flow reached 14.89 billion, marking a significant increase of 115.11% year-on-year, indicating strong profitability and risk resilience [4][5]. Group 3: Strategic Projects - Zhejiang Medicine is investing 16.85 billion in the Changbei Biological Project, which aims to enhance its vitamin intermediate production and develop high-value-added products, with expected annual sales of 9 billion and a gross profit of 2.86 billion [4]. - The project is planned in two phases, with the first phase focusing on vitamin intermediates and expected to complete by November 2027 [4]. Group 4: Shareholder Engagement - To enhance team engagement and operational vitality, Zhejiang Medicine is implementing a share buyback and stock incentive plan, having completed a buyback of 2 billion and initiated a new stock incentive plan for 875 employees [5].

Group 1 - Hekang New Energy's subsidiary received a government subsidy of 6 million yuan, accounting for 58.27% of the company's latest audited net profit attributable to shareholders [1] - Anhui Construction won two major EPC projects with a total bid price of 2.603 billion yuan [2] - Tianrun Dairy's wholly-owned subsidiary received a government subsidy of 7.9094 million yuan, representing 18.12% of the company's audited net profit for 2024 [2] Group 2 - Yunnan Gold's subsidiary obtained a mining license for the Xinxiao County Tanxi Tungsten Mine, with a production capacity of 990,000 tons per year [5][22] - Yanzhou Coal Energy plans to acquire 100% equity of a high-end support company for 345 million yuan [6] - Heng Rui Pharmaceutical received approval for multiple drug clinical trials, including Sulfate Amexitin tablets [8] Group 3 - Huazhi Jie plans to invest 157 million yuan to establish five wholly-owned subsidiaries to expand its global strategy [1] - Junting Hotel's controlling shareholder is planning a change of control, leading to a continued suspension of trading [4] - Funi Technology's shareholder plans to reduce its stake by up to 1.68% [10] Group 4 - Midea Group's subsidiary received a government subsidy of 6 million yuan, which is 58.27% of the company's latest audited net profit [1] - Hunan Gold's subsidiary obtained a mining license for tungsten, iron, and silver, with a production scale of 990,000 tons per year [5][22] - Xin Hua Pharmaceutical received approval for the listing application of Acetate Prednisone raw material [24][25] Group 5 - Zhejiang Pharmaceutical plans to spin off its subsidiary for a listing on the Hong Kong Stock Exchange [28] - Kesheng Technology plans to invest 61.2 million yuan to acquire 51% of Shenzhen Guanding [30] - Tian Shan Aluminum's 1.4 million tons electrolytic aluminum green low-carbon energy efficiency improvement project has commenced production [38]